Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 8/20 | 0.37 |
| ▸ | BRAF | P15056 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10043740 | 0.89 | RAF1 (0.43) | SYKRAF1BRAFALDH1A1POLB | |
| SCHEMBL10072021 | 0.82 | SYK (0.59) | SYKRAF1BRAF | |
| SCHEMBL10043661 | 0.82 | SYK (0.55) | SYKRAF1BRAF | |
| SCHEMBL10043839 | 0.81 | SYK (0.47) | SYKRAF1BRAF | |
| SCHEMBL10043698 | 0.80 | SYK (0.70) | SYKRAF1BRAF | |
| SCHEMBL10043705 | 0.80 | MAPT (0.54) | SYKALDH1A1POLB | |
| SCHEMBL10043683 | 0.80 | NPC1 (0.46) | SYKALDH1A1POLB | |
| SCHEMBL10043697 | 0.80 | SYK (0.43) | SYKRAF1BRAFPOLB | |
| SCHEMBL10043751 | 0.80 | SYK (0.53) | SYKRAF1BRAF | |
| SCHEMBL10043951 | 0.80 | SYK (0.51) | SYKRAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106068-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2012-01-31 | — | — | US | disclosed |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2010-04-01 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | SYK 42/4885DGAT1 4811/4885NTRK1 138/4885 |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | SYK 42/4885DGAT1 4811/4885NTRK1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.